Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; AstraZeneca; Athenex; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech; Genomic Health, Inc.; KCI USA, Inc.; MacroGenics, Inc.; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; Pacira Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; and Seattle Genetics, Inc.

37th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™

Release Date: May 29, 2020
Expiration Date: May 29, 2021

Activity Overview

Strategies for achieving the best possible outcomes for patients with breast cancer are prone to rapid change because of the pace at which advances in patient care across the cancer care continuum emerge. The Annual Miami Breast Cancer Conference® brings together breast cancer specialists to highlight state-of-the-art multidisciplinary patient care. This year’s conference was no exception, with an agenda that featured clinical updates in local, regional, and systemic therapies; timely practice management and policy concerns; exploration of clinical controversies; patient-centered care; and patient‒clinician communication.

This online CME/CE-certified educational activity based on content presented at the 37th Annual Miami Breast Cancer Conference® consists of a series of interviews with Aditya Bardia, MD, MPH; Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCS(C); Sara Hurvitz, MD; Hope S. Rugo, MD, FASCO; and Debu Tripathy, MD, during which they discuss their approaches toward clinical cases and other topics important to the practicing community clinician. In addition, excerpts from the tumor board sessions feature a panel of renowned experts weighing in on challenging clinical cases, as well as a thought-provoking exploration of current and emerging clinical data that are changing outcomes for patients with breast cancer.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; AstraZeneca; Athenex; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech; Genomic Health, Inc.; KCI USA, Inc.; MacroGenics, Inc.; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; Pacira Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; and Seattle Genetics, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other healthcare professionals interested in the treatment of breast cancer are also welcomed to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Incorporate evidence-based molecular and genomic biomarkers, multi-gene prognostic assays, and tumor subtype information, as appropriate, to guide clinical decision-making and optimize outcomes for individual patients
  • Summarize expert guidelines and evidence from clinical trials that support the use of genomic and molecular tools to individualize and inform treatment decisions for patients with breast cancer
  • Implement evidence-based multimodal treatment strategies, integrating surgery, radiation, and systemic therapy, when appropriate, to ensure optimal outcomes for patients with nonmetastatic breast cancer
  • Coordinate a multidisciplinary approach to prevent, mitigate, or manage treatment-related adverse events for patients with breast cancer to optimize outcomes
  • Integrate recent clinical trial data and expert guidelines regarding systemic therapies into treatment planning in order to provide evidence-based state-of-the-art care for patients with breast cancer
  • Identify ongoing clinical trials of emerging agents and strategies that offer additional treatment options for patients with breast cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH
Director, Precision Medicine
Center for Breast Cancer
Assistant Professor, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: Biotheranostics, Daiichi Sankyo/AstraZeneca, Genentech/Roche, Immunomedics, Merck, Novartis, Pfizer, Radius Health, Sanofi; Consultant: Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech/Roche, Immunomedics, Merck, Novartis, Pfizer, Phillips, Radius Health, Sanofi.

Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCS(C)
Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCS(C)
Professor of Surgery, Oncology
Yale Comprehensive Cancer Center
Yale University School of Medicine
New Haven, CT

Disclosures: Other: Protean BioDiagnostics Board of Directors.

Sara A. Hurvitz, MD
Sara A. Hurvitz, MD
Director, Breast Cancer Clinic
Co-Director, Santa Monica-UCLA Outpatient Hematology/Oncology Practice Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosures: Grant Research Support: Ambrx, Amgen, Arvinas, Bayer, Cascadian Therapeutics, Daiichi Sankyo, Dignitana, Eli Lilly, Genentech, GlaxoSmithKline, Immunomedics, MacroGenics, Medivation, Merrimack Pharmaceuticals, Novartis, OBI Pharma, Pfizer, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Roche, Seattle Genetics; Travel: Eli Lilly, Novartis, OBI Pharma.

Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research Support: Pfizer, Merck, Novartis, Eli Lilly, Genentech, OBI Pharma, Odonate Therapeutics, Daiichi Sankyo, Eisai, Seattle Genetics, MacroGenics, Immunomedics; Travel: Amgen, AstraZeneca, Daiichi Sankyo, MacroGenics, Merck, Mylan, Pfizer, Puma Biotechnology.

Debu Tripathy, MD
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Novartis, Polyphor; Consultant: AstraZeneca, GlaxoSmithKline, Genomic Health, Novartis, Pfizer.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By